[go: up one dir, main page]

AU2423488A - Pharmaceutical presentation potentializing the cytotrophic effect of animal and/or human sera and/or antitissue antibodies - Google Patents

Pharmaceutical presentation potentializing the cytotrophic effect of animal and/or human sera and/or antitissue antibodies

Info

Publication number
AU2423488A
AU2423488A AU24234/88A AU2423488A AU2423488A AU 2423488 A AU2423488 A AU 2423488A AU 24234/88 A AU24234/88 A AU 24234/88A AU 2423488 A AU2423488 A AU 2423488A AU 2423488 A AU2423488 A AU 2423488A
Authority
AU
Australia
Prior art keywords
cytotrophic
potentializing
animal
effect
human sera
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24234/88A
Inventor
Pascal Berdal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2423488A publication Critical patent/AU2423488A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
AU24234/88A 1987-09-15 1988-09-14 Pharmaceutical presentation potentializing the cytotrophic effect of animal and/or human sera and/or antitissue antibodies Abandoned AU2423488A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8712797 1987-09-15
FR8712797A FR2620335A1 (en) 1987-09-15 1987-09-15 PHARMACEUTICAL PRESENTATION POTENTIALIZING THE CYTOTROPHIC EFFECT OF SERUMS AND / OR ANTIBODY ANTIBODIES ANIMALS AND / OR HUMANS

Publications (1)

Publication Number Publication Date
AU2423488A true AU2423488A (en) 1989-04-17

Family

ID=9354933

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24234/88A Abandoned AU2423488A (en) 1987-09-15 1988-09-14 Pharmaceutical presentation potentializing the cytotrophic effect of animal and/or human sera and/or antitissue antibodies

Country Status (4)

Country Link
EP (1) EP0354930A1 (en)
AU (1) AU2423488A (en)
FR (1) FR2620335A1 (en)
WO (1) WO1989002268A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2101041B1 (en) * 1970-08-12 1974-02-01 Cassenne Lab Sa
JPS5837285B2 (en) * 1975-05-29 1983-08-15 カブシキガイシヤ ミドリジユウジ It is very difficult to understand the situation.
CA1143289A (en) * 1978-10-17 1983-03-22 Lee R. Beck Microparticle drug delivery system
FR2587217B1 (en) * 1985-03-18 1991-10-18 Berdal Pascal IMMUNOMODULANT PHARMACEUTICAL PREPARATIONS
FR2584294B1 (en) * 1985-07-08 1992-02-21 Berdal Pascal PHARMACEUTICAL COMPOSITIONS WITH A CYTOTROPHIC VIEW
EP0209493A3 (en) * 1985-07-16 1988-05-04 Ciba-Geigy Ag Prophylaxis and treatment of whooping cough

Also Published As

Publication number Publication date
EP0354930A1 (en) 1990-02-21
WO1989002268A1 (en) 1989-03-23
FR2620335A1 (en) 1989-03-17

Similar Documents

Publication Publication Date Title
AU2650988A (en) Vectors and compounds for direct expression of activated human protein c
FI885589L (en) Preparation and use of protein product
AU1454988A (en) Stable pharmaceutical w/o emulsion composition
NO903906L (en) FOOD MATERIALS AND PROCEDURES FOR THE PREPARATION OF THIS.
PT87237A (en) PROCESS FOR THE PREPARATION OF BIFUNCTIONAL PROTEINS AND PHARMACEUTICAL COMPOUNDS CONTAINING THEM
FI900808A7 (en) Human mannose-binding protein
AU2182588A (en) Immunoassay and biological constructs for use therein
AU8316587A (en) Pharmaceutical compositions and their use
EP0295402A3 (en) Latex for immobilization of physiologically active substance and latex reagent using the latex
AU1370088A (en) Use of antigenic substances for the prophylaxis or therapy of disorders and diseases within the gastrointestinal tract of animals and humans
NO882940L (en) PROCEDURE FOR THE PREPARATION OF CASTANOSPERMINESTERS AND Glycosides.
DK439589D0 (en) FLUOR-SUBSTITUTED 4'-DEMETHYLEPIPODOPHYLLOTOX INGREDIENTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME
AU8891691A (en) Human proteins having anticoagulant and anti-inflammatory activity
NO892269D0 (en) NON-HYPERGYLYCOSYLED HEPATITY B VIRUS PROTEINS AND EXPRESSION "CASSETTE" AND PROCEDURE FOR THE PREPARATION OF THE PROTEINS.
AU2845989A (en) Use of milk proteins for the manufacture of an anti-viral medicament
AU6527390A (en) Pharmaceutical compositions for the treatment of ataxy and equilibrium problems
NZ227594A (en) Human interleukin-1alpha and preparations thereof
NO881713L (en) PROCEDURE FOR THE PREPARATION OF DI-T-BUTYLPHENYL-ALKYL AND BENZYLETHERS.
AU1450788A (en) Thiophene-2-carbox-amide derivatives and their pharmaceutical use
AU2423488A (en) Pharmaceutical presentation potentializing the cytotrophic effect of animal and/or human sera and/or antitissue antibodies
AU1996388A (en) Proteins and protein compositions and their use
DK320288A (en) SACAROAS CHORBIC ACID EASTERS AND THE PREPARATION AND APPLICATION OF THEREOF
AU6269190A (en) Antibodies and proteins
AU2847289A (en) Use of tnf and lt for the preparation of drugs
PT87555A (en) PROCESS FOR THE PREPARATION AND ISOLATION OF HUMAN SPLEIN AND PHARMACEUTICAL COMPOUNDS CONTAINING IT